xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 6, 2009 : CVM, CPD, TMI and HH

CEL-SCI Corporation (NYSE Amex: CVM | Quote | Chart | News | PowerRating) trading at $1.17 on a volume of 9.27M shares

In a press release out on November 6, CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine

VIENNA, Va., Nov 06, 2009 -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that an Institutional Review Board of The Johns Hopkins University School of Medicine (Johns Hopkins) has given clearance for the Company's first clinical study to proceed. As a result, Johns Hopkins will host the study, which will be led by Principal Investigator Jonathan M. Zenilman, MD, Professor of Medicine, Johns Hopkins School of Medicine and Chief of Infectious Diseases Division, Johns Hopkins Bayview Medical Center. As previously announced, this initial study will involve taking blood from hospitalized, laboratory-confirmed H1N1 patients and activating their cells with the LEAPS H1N1 investigational therapy in order to assess the cells' response as the basis for the planned future treatment of this patient population under a next-stage clinical trial protocol.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy to prevent and treat swine and other influenzas using its L.E.A.P.S. technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD | Quote | Chart | News | PowerRating) trading at $16.51 per share on trading volume of 20,528 shares.

In a press release out on November 6, Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution

DETROIT, Nov 06, 2009 -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD | Quote | Chart | News | PowerRating) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA) for generic Acular(R) ophthalmic solution on the first day following patent expiration. This strength of ketorolac is therapeutically equivalent to Acular(R) Ophthalmic Solution, 0.5%, from Allergan, Inc. Ketorolac tromethamine ophthalmic solution is indicated for temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. Acular(R) ophthalmic solution has annual sales of approximately $40 million in the US.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

China MediaExpress Holdings, Inc. (NYSE Amex: TMI; TMI/U; TMI/WS) trading at $10.85 on a volume of 383,901 shares

In a press release out on November 6, China MediaExpress Holdings, Inc. Repurchases and Retires 1.9 Million Warrants in Private Transaction

FUJIAN, China, Nov 06, 2009 -- China MediaExpress Holdings, Inc. (NYSE Amex: TMI; TMI/U; TMI/WS) ("CME" or the "Company") today announced that it has repurchased and retired a total of 1.9 million of its publicly-traded warrants in a private transaction, for an aggregate purchase price of $950,000 ($0.50 per warrant). The repurchase of these warrants, which represent approximately 19% of all of CME's publicly-traded warrants, was made pursuant to a warrant repurchase agreement dated October 12, 2009, which was amended on November 1, 2009. All of the terms of the remaining publicly-traded warrants remain the same.

About CME

CME, through contractual arrangements with Fujian Fenzhong, an entity majority owned by CME'S former majority shareholder, operates the largest television advertising network on inter-city express buses in China. While CME has no direct equity ownership in Fujian Fenzhong, through the contractual agreements CME receives the economic benefits of Fujian Fenzhong's operations. Fujian Fenzhong generates revenue by selling advertisements on its network of television displays installed on over 18,000 express buses originating in thirteen of China's most prosperous regions, including the five municipalities of Beijing, Shanghai, Guangzhou, Tianjin and Chongqing and eight economically prosperous provinces, namely Guangdong, Jiangsu, Fujian, Sichuan, Hebei, Anhui, Hubei and Shandong which generate nearly half of China's GDP.

Hooper Holmes (NYSE Amex: HH | Quote | Chart | News | PowerRating) trading at $0.99 on a volume of 516,266 shares

In a press release out on November 6, Hooper Holmes Announces Third Quarter 2009 Results

BASKING RIDGE, N.J., Nov 06, 2009 -- Hooper Holmes (NYSE Amex: HH | Quote | Chart | News | PowerRating) today announced financial results for the three and nine months ended September 30, 2009.

Consolidated revenues totaled $43.8 million for the third quarter of 2009, representing a 7% revenue decline from the $47.2 million in the third quarter of 2008. This is an improvement for the third quarter of 2009 in comparison to the 10% revenue decline experienced in the first half of 2009. The Company recorded a net loss of $0.7 million for the third quarter of 2009, or $(0.01) per share compared to a net loss of $2.7 million, or $(0.04) per share in 2008. The net loss for the third quarter of 2009 includes a non-cash charge of $0.6 million attributable to increased depreciation expense resulting from a reduction in the estimated useful life of the Company's current IT system. In addition, the net loss for the third quarter of 2009 includes $0.3 million of restructuring and other charges. The net loss for the third quarter of 2008 included a loss from discontinued operations of $0.6 million.

About Hooper Holmes

Hooper Holmes is a leader in collecting personal health data and transforming it into useful information, enabling customers to take actions that manage or reduce their risks and expenses. As a leading provider of risk assessment services for the insurance industry, Hooper Holmes provides insurers with the widest range of medical exam, data collection, laboratory testing and underwriting services in the industry.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com
e-mail: Info@xtremepicks.com
WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Cel-Sci Corp (CVM) CVM. Cel-Sci Corp (CVM) has Short Term PowerRatings at TradingMarkets. Details on Cel-Sci Corp (CVM) Short Term PowerRatings is available at This Link.

For full details on Caraco Pharm Labs (CPD) CPD. Caraco Pharm Labs (CPD) has Short Term PowerRatings at TradingMarkets. Details on Caraco Pharm Labs (CPD) Short Term PowerRatings is available at This Link.

For full details on Hooper Holmes Inc (HH) HH. Hooper Holmes Inc (HH) has Short Term PowerRatings at TradingMarkets. Details on Hooper Holmes Inc (HH) Short Term PowerRatings is available at This Link.